HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections.

Abstract
In an open, randomized study, the effect of pefloxacin (400 mg b.i.d.) was compared with that of cefotaxime (1 g t.i.d.) in the treatment of complicated urinary tract infections. In total 87 patients entered the study under the clinical diagnosis of complicated urinary tract infection, of whom 49 were eligible for evaluation. Most isolates (90%) belonged to the family of Enterobacteriaceae. Isolates were eradicated from 96% (28/29) of patients treated with pefloxacin and 89% (16/18) of those receiving cefotaxime 48 h after the end of therapy. After one week a total of 92% (22/24) of patients treated with pefloxacin were culture negative, while in the group treated with cefotaxime a total of 82% (9/11) were culture negative. After four to six weeks, 68% (13/19) in the pefloxacin and 80% (8/10) in the cefotaxime study group showed a negative urine culture (difference non-significant; p greater than 0.5). Clinical cure at the end of treatment was 97% (30/31) in the pefloxacin group vs. 89% (16/18) in the cefotaxime group. Both groups showed similar relapse and reinfection rates at 48 h and one week after therapy. Adverse effects were mild and reversible for both drugs. It is concluded that pefloxacin is a safe and effective alternative for treatment of complicated urinary tract infection.
AuthorsC Timmerman, I Hoepelman, J de Hond, T Boon, L Schreinemachers, H Mensink, J Verhoef
JournalInfection (Infection) 1992 Jan-Feb Vol. 20 Issue 1 Pg. 34-7 ISSN: 0300-8126 [Print] Germany
PMID1563810 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Pefloxacin
  • Cefotaxime
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Cefotaxime (adverse effects, therapeutic use)
  • Enterobacteriaceae Infections (drug therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pefloxacin (adverse effects, therapeutic use)
  • Pyelonephritis (drug therapy)
  • Recurrence
  • Time Factors
  • Urinary Tract Infections (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: